Overall, the inhibitory actions triggered by E4 through the GPER/ERK/SERPINB2 pathway in TNBC cells (Fig. 7) may provide novel insights concerning the biological effects of E4 in the aggressive breast tumor subtype namely TNBC. The gene discussed is MAPK1; the disease is breast neoplasm.